Increasing incidence and antimicrobial resistance in Escherichia coli bloodstream infections: a multinational population-based cohort study.
Adolescent
Adult
Aged
Aged, 80 and over
Anti-Infective Agents
/ pharmacology
Australian Capital Territory
/ epidemiology
Canada
/ epidemiology
Child
Child, Preschool
Cohort Studies
Drug Resistance, Bacterial
Escherichia coli
/ drug effects
Escherichia coli Infections
/ drug therapy
Female
Finland
/ epidemiology
Humans
Incidence
Infant
Internationality
Male
Middle Aged
Sepsis
/ drug therapy
Sweden
/ epidemiology
Young Adult
Antimicrobial resistance
Bacteremia
Bloodstream infection
Escherichia coli
Incidence rate
Population-based
Third-generation cephalosporins
Journal
Antimicrobial resistance and infection control
ISSN: 2047-2994
Titre abrégé: Antimicrob Resist Infect Control
Pays: England
ID NLM: 101585411
Informations de publication
Date de publication:
06 09 2021
06 09 2021
Historique:
received:
02
11
2020
accepted:
23
08
2021
entrez:
7
9
2021
pubmed:
8
9
2021
medline:
1
3
2022
Statut:
epublish
Résumé
Escherichia coli is an important pathogen in humans and is the most common cause of bacterial bloodstream infections (BSIs). The objectives of our study were to determine factors associated with E. coli BSI incidence rate and third-generation cephalosporin resistance in a multinational population-based cohort. We included all incident E. coli BSIs (2014-2018) from national (Finland) and regional (Australia [Canberra], Sweden [Skaraborg], and Canada [Calgary, Sherbrooke, and western interior]) surveillance. Incidence rates were directly age and sex standardized to the European Union 28-country 2018 population. Multivariable negative binomial and logistic regression models estimated factors significantly associated with E. coli BSI incidence rate and third-generation cephalosporin resistance, respectively. The explanatory variables considered for inclusion in both models were year (2014-2018), region (six areas), age (< 70-years-old and ≥ 70-years-old), and sex (female and male). We identified 31,889 E. coli BSIs from 40.7 million person-years of surveillance. Overall and third-generation cephalosporin-resistant standardized rates were 87.1 and 6.6 cases/100,000 person-years, respectively, and increased 14.0% and 40.1% over the five-year study. Overall, 7.8% (2483/31889) of E. coli BSIs were third-generation cephalosporin-resistant. Calgary, Canberra, Sherbrooke, and western interior had significantly lower E. coli BSI rates compared to Finland. The significant association between age and E. coli BSI rate varied with sex. Calgary, Canberra, and western interior had significantly greater odds of third-generation cephalosporin-resistant E. coli BSIs compared to Finland. Compared to 2014, the odds of third-generation cephalosporin-resistant E. coli BSIs were significantly increased in 2016, 2017, and 2018. The significant association between age and the odds of having a third-generation cephalosporin-resistant E. coli BSI varied with sex. Increases in overall and third-generation cephalosporin-resistant standardized E. coli BSI rates were clinically important. Overall, E. coli BSI incidence rates were 40-104% greater than previous investigations from the same study areas. Region, sex, and age are important variables when analyzing E. coli BSI rates and third-generation cephalosporin resistance in E. coli BSIs. Considering E. coli is the most common cause of BSIs, this increasing burden and evolving third-generation cephalosporin resistance will have an important impact on human health, especially in aging populations.
Sections du résumé
BACKGROUND
Escherichia coli is an important pathogen in humans and is the most common cause of bacterial bloodstream infections (BSIs). The objectives of our study were to determine factors associated with E. coli BSI incidence rate and third-generation cephalosporin resistance in a multinational population-based cohort.
METHODS
We included all incident E. coli BSIs (2014-2018) from national (Finland) and regional (Australia [Canberra], Sweden [Skaraborg], and Canada [Calgary, Sherbrooke, and western interior]) surveillance. Incidence rates were directly age and sex standardized to the European Union 28-country 2018 population. Multivariable negative binomial and logistic regression models estimated factors significantly associated with E. coli BSI incidence rate and third-generation cephalosporin resistance, respectively. The explanatory variables considered for inclusion in both models were year (2014-2018), region (six areas), age (< 70-years-old and ≥ 70-years-old), and sex (female and male).
RESULTS
We identified 31,889 E. coli BSIs from 40.7 million person-years of surveillance. Overall and third-generation cephalosporin-resistant standardized rates were 87.1 and 6.6 cases/100,000 person-years, respectively, and increased 14.0% and 40.1% over the five-year study. Overall, 7.8% (2483/31889) of E. coli BSIs were third-generation cephalosporin-resistant. Calgary, Canberra, Sherbrooke, and western interior had significantly lower E. coli BSI rates compared to Finland. The significant association between age and E. coli BSI rate varied with sex. Calgary, Canberra, and western interior had significantly greater odds of third-generation cephalosporin-resistant E. coli BSIs compared to Finland. Compared to 2014, the odds of third-generation cephalosporin-resistant E. coli BSIs were significantly increased in 2016, 2017, and 2018. The significant association between age and the odds of having a third-generation cephalosporin-resistant E. coli BSI varied with sex.
CONCLUSIONS
Increases in overall and third-generation cephalosporin-resistant standardized E. coli BSI rates were clinically important. Overall, E. coli BSI incidence rates were 40-104% greater than previous investigations from the same study areas. Region, sex, and age are important variables when analyzing E. coli BSI rates and third-generation cephalosporin resistance in E. coli BSIs. Considering E. coli is the most common cause of BSIs, this increasing burden and evolving third-generation cephalosporin resistance will have an important impact on human health, especially in aging populations.
Identifiants
pubmed: 34488891
doi: 10.1186/s13756-021-00999-4
pii: 10.1186/s13756-021-00999-4
pmc: PMC8422618
doi:
Substances chimiques
Anti-Infective Agents
0
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
131Subventions
Organisme : CIHR
Pays : Canada
Informations de copyright
© 2021. The Author(s).
Références
Clin Microbiol Infect. 2013 May;19(5):465-71
pubmed: 22616816
J Infect. 2008 Dec;57(6):441-8
pubmed: 18990451
J Antimicrob Chemother. 2009 Jul;64(1):169-74
pubmed: 19435736
J Antimicrob Chemother. 2011 Feb;66(2):398-407
pubmed: 21106563
Euro Surveill. 2016 Sep 1;21(35):
pubmed: 27608263
Clin Microbiol Rev. 2014 Oct;27(4):647-64
pubmed: 25278570
J Infect. 2014 Jul;69(1):51-9
pubmed: 24576825
Am J Trop Med Hyg. 2019 Apr;100(4):943-951
pubmed: 30793684
BMC Infect Dis. 2013 Aug 21;13:385
pubmed: 23964864
Clin Microbiol Infect. 2013 Jun;19(6):492-500
pubmed: 23398633
BMC Res Notes. 2009 Jul 22;2:146
pubmed: 19624839
Clin Microbiol Infect. 2015 Mar;21(3):251.e1-8
pubmed: 25698659
Lancet Infect Dis. 2008 Mar;8(3):159-66
pubmed: 18291338
Arch Intern Med. 2007 Apr 23;167(8):834-9
pubmed: 17452548
Clin Infect Dis. 2021 Apr 8;72(7):1211-1219
pubmed: 32406495
Southeast Asian J Trop Med Public Health. 2012 Sep;43(5):1169-77
pubmed: 23431823
Clin Microbiol Infect. 2012 Jun;18(6):E170-6
pubmed: 22512663
Clin Microbiol Infect. 2008 Nov;14(11):1041-7
pubmed: 19040476
BMC Infect Dis. 2017 Mar 11;17(1):205
pubmed: 28284196
Med J Aust. 2008 Feb 18;188(4):209-13
pubmed: 18279126
Epidemiol Infect. 2008 Jan;136(1):108-14
pubmed: 17335630
J Infect. 2015 Dec;71(6):667-74
pubmed: 26380898
Epidemiol Infect. 2016 Aug;144(11):2440-6
pubmed: 26996433
PLoS One. 2019 Dec 5;14(12):e0225700
pubmed: 31805110